Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials

Inclusion Criteria:

- Patients who were assigned to an axitinib containing treatment arm in a previous
clinical trial

- Patients who were receiving axitinib tablets at the time their previous trial ended

- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous AG-013736 protocol should be
used to determine stable or responding disease).

- Patients who have progressive disease (PD) but have experienced "clinical benefit"
as defined in the study protocol

Exclusion Criteria:

- Patients may not participate in this trial if the conditions for continuing treatment
in the previous AG-013736 protocol are not met